Barbara Ryan Quotes (28 Quotes)

We believe Merck has put in place an aggressive, but achievable strategic plan.

Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.

There is a 10-year lag in RD spending, ... The spending that they're doing today isn't going to be visible in terms of products for quite some time.

By our calculation, Pfizer's consumer business has an implied market value of 4.6 billion but could be sold for 2 to 2.5 times that amount, or 10 billion.

The only company which is a clear growth vehicle in our view is Schering-Plough.

It's a wild card. If it works, great, but I don't think there's a tremendous amount of visibility right now. It's been a long time in the making at Merck and there have been disappointments along the way. The HIV virus is crafty, and there are many different strains.

Despite the pressures that Pfizer has faced and will face on the top line, the company will be able to deliver on their earnings target, in part aided by introduction of their new drugs.

You're going to see a much more transparent and humbled management team with a lot more detail and granularity on a whole lot of issues, which is not characteristic of Pfizer historically. They have heard their shareholders loud and clear and recognize that they need to be transparent and more visible.

Recent results provide clear evidence of the turnaround at Schering-Plough and the positive momentum of the cholesterol joint venture.

It's hard to think of a government agency Schering-Plough wasn't being investigated by.

The company has gone through a radical transformation,

This is as good as it gets for Pfizer. They won a victory on both patents -- well beyond our expectations.

Lilly has been more innovative than most other companies but done worse at execution. There's betting on a pipeline that hasn't panned out in the past.

I just don't think it's a big deal, ... There certainly isn't any evidence linking Viagra with these reports. There is a risk with this form of blindness from diabetes and cardiovascular disease, and those are also risks for erectile dysfunction or impote

The restructuring is not heroic by any stretch of the imagination.

I think people are coming to the realization that this is going to be a marathon that's going to be running for a period of time and Merck is unlikely to pay any money out over the next few years.

The only way this company can improve their earnings is through pursuing a merger or by being acquired. It's not very innovative, but it's what they're going to have to do.

been a long time in coming.

New drugs are not going to build billion dollar sales in a few weeks. It takes years to do that.

How much we do depends on how much of the financing plan comes through.

In our view, Pfizer is in fact defensive and has demonstrated that it can weather the blows in a measured fashion due to its dramatic scale advantage and strong balance sheet.

Investors and company managements will likely focus on the benefits of restructuring and the improving new product flow for late 2006.

We're left with a company with a litany of problems and a management that has zero credibility. I think some heads will roll and they will be very vulnerable to take-out.

I think it's sort of a meaningless statement from their perspective and they're trying to grab victory out of this by taking a posture that makes them look altruistic, ... I also think they're trying to look like they're being good corporate citizens. Since Bristol has been investigated by just about every government agency, they have a lot to make up for in that regard.

So far the integration appears to be going well. The economics of the merger are going to be quite strong. We're somewhat disappointed in the near-term revenue trend and are neutral on the stock in the short run.

Although the full force of the impact of Hurricanes Katrina and Rita will not be fully known for some time, it is clear that the scope of the devastation is unprecedented for the local economies and is projected to slow U.S. economic activity in the third and fourth quarters.

They can get a good price for it and it's probably undervalued in their portfolio. It's not so much about them getting out of that business much as it's about unleashing shareholder value.

They made the consensus numbers even after taking that charge. The stock has already been pummeled in the last few years. I think with all things taken into account, the earnings were a little better than expected.